S Biomedics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
S Biomedics develops stem-cell therapies, medicines made from living cells that are grown and processed outside the body, aimed at treating hard-to-cure, rare, and chronic diseases where conventional drugs have limited effect.
Its products and pipeline target patients and healthcare providers across multiple disease areas. Listed on KOSDAQ, Korea's tech and small-cap board, the company's core business is stem-cell therapy research, development, and production, while a subsidiary handles medical devices and anti-ageing cosmetic products.
Summary is AI-generated and may contain errors · figures from DART filings
Its subsidiary, S-Tepharm, was established as a dedicated sales and manufacturing entity and operates its own production facility for anti-ageing aesthetic products.
S Biomedics in five facts
What does S Biomedics do?
S Biomedics develops stem-cell therapies, medicines made from living cells that are grown and processed outside the body, aimed at treating hard-to-cure, rare, and chronic diseases where conventional drugs have limited effect.
Where is S Biomedics listed and in which sector?
S Biomedics (Korean name: 에스바이오메딕스) trades under KRX code 304360 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is S Biomedics?
Its market capitalisation was US$199.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were S Biomedics's latest annual revenue and operating profit?
For fiscal year 2025, S Biomedics reported revenue of US$12.5M, an operating loss of US$6.3M and net income of US$802.2K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 20.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersAug 31
- Early redemption of convertible bonds (incl. overseas CBs)
S Biomedics acquired US$265K of its 5th-issue convertible bonds on August 13, 2026 following a bondholder's exercise of a put option, at a conversion price of US$23.26/share (adjusted January 13, 2026), leaving US$879K outstanding; the company will later decide whether to resell or retire the acquired bonds.
Capital raise · Aug 13 - Material event report (convertible bonds)
S Biomedics disclosed convertible bonds to raise US$15.1M, about 7.8% of its market value.
Capital raise · Apr 14 - Material event report (rights offering)
S Biomedics disclosed convertible bonds to raise US$12.1M, about 6.3% of its market value.
Capital raise · Apr 14 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
S Biomedics reported consolidated results for FY2025: revenue of US$11.6M (+20.5% year on year), an operating loss of US$5.75M and a net loss of US$4.84M.
Earnings · Feb 27